ScripITM Isotope Technologies Munich is preparing the complex logistics and manufacturing it will need for commercial launch of ITM-11 (non-carrier-added 177 Lu-edotreotide), its radiopharmaceutical candid
ScripThe end of 2024 brought near-term cash shortfalls into focus at several biopharmaceutical companies, while others completed their assessments of potential alternatives to shutting their doors as capit
ScripOS Therapies Incorporated launched the 14th biopharmaceutical company initial public offering in the US in 2024 on 31 July, selling 1.6 million shares at $4 each to gross $6.4m in the smallest IPO so
ScripAstraZeneca PLC first involved itself with Fusion Pharmaceuticals Inc. in 2020, striking a deal to develop novel alpha emitters. Now the UK giant has made a more definitive move, paying $2bn upfron